MedCity News

DECEMBER 30, 2024

One Phase 3 test of Auvelity met its main goal in Alzheimers agitation while the drugs other pivotal trial showed numerical improvement that fell short of statistical significance. Axsome Therapeutics aims to offer an alternative to Rexulti, a Lundbeck and Otsuka Pharmaceutical product that is the only FDA-approved Alzheimers agitation drug. The post Axsome Aims for FDA Filing in Alzheimers Agitation Despite Mixed Bag of Phase 3 Data appeared first on MedCity News.

FDA 93

FDA Pharmaceutical products Pharmaceutical Biopharma 93

pharmaphorum

DECEMBER 30, 2024

BMS beats MSD to the US subcutaneous PD-1 inhibitor market after Opdivo Qvantiq is cleared across nearly all the indications of the IV form

Marketing 80

Marketing 80

MedCity News

DECEMBER 30, 2024

Opdivo Qvantig, administered by injection in less than five minutes, is now FDA approved for solid tumor indications covered by Opdivo, a 30-minute intravenous infusion. The new product will help Bristol Myers Squibb compete with biosimilars as Opdivo faces looming patent expiration. The post Bristol Myers Squibb Wins FDA Nod for Injectable Version of Blockbuster Cancer Drug appeared first on MedCity News.

FDA 93

FDA Biopharma Pharma 93

pharmaphorum

DECEMBER 30, 2024

Daiichi Sankyo has claimed its first approval, in Japan, for TROP2-targeting antibody-drug conjugate (ADC) datopotamab deruxtecan

71

71

Advertiser: ZoomInfo

Savvy B2B marketers know that a great account-based marketing (ABM) strategy leads to higher ROI and sustainable growth. In this guide, we’ll cover: What makes for a successful ABM strategy? What are the key elements and capabilities of ABM that can make a real difference? How is AI changing workflows and driving functionality? This Martech Intelligence Report on Enterprise Account-Based Marketing examines the state of ABM in 2024 and what to consider when implementing ABM software.

Marketing

MedCity News

DECEMBER 30, 2024

The Uno Savings Guide is a free resource that helps people check their eligibility for financial benefit programs, like Medicaid, Medicare Savings Programs and SNAP. The post Uno Health Unveils Tool to Help Americans Check Eligibility for Financial Benefits appeared first on MedCity News.

77

77

PharmaTech

DECEMBER 30, 2024

The PharmTech Group editors present our most popular interviews from 2024.

64

64

Spotio

DECEMBER 30, 2024

Growing a business is no easy taskespecially when your teams operate in silos. Revenue Operations (RevOps) is here to change that. By aligning sales, marketing, customer success, and finance, RevOps ensures your team is rowing in the same direction to drive sustainable growth. In this guide, well explore what RevOps is, why its a crucial driver of modern business success, and how to create an effective RevOps strategy that unites your teams and streamlines processes across all sales channelswhet

Sales 52

Sales Prospecting CRM Leads 52

Pharmaceutical Technology

DECEMBER 30, 2024

MTX-COVAB is under clinical development by Memo Therapeutics and currently in Phase I for Coronavirus Disease 2019 (COVID-19).

52

52

Pharmaceutical Commerce

DECEMBER 30, 2024

A dive into the top articles in this sector making waves this year.

Pharma 52

Pharma Patients 52

PharmaTech

DECEMBER 30, 2024

In this first of a four-part series, the authors provide an introduction to a practical approach for establishing specification equivalence. The regulatory basis and compliance examples from FDA observations and warning letters are included to support the need for an effective process.

FDA 52

FDA 52

Advertisement

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

Sales Management

Pharmaceutical Technology

DECEMBER 30, 2024

The US FDA has granted approval for Bristol Myers Squibbs (BMS) Opdivo Qvantig for subcutaneous use to treat various solid tumours.

FDA 52

FDA 52

PharmExec

DECEMBER 30, 2024

In this part of his Pharmaceutical Executive video interview, Dr. Lawrence B. Werlin, MD, FACOG of HRC Fertility (@md.lawrence.werlin on TikTok), how new radiological techniques are revolutionizing the diagnosis of conditions like endometriosis and the impact it will have on patients.

Pharmaceutical 52

Pharmaceutical Patients 52

Pharmaceutical Technology

DECEMBER 30, 2024

Tevimbra is already approved in the US for the treatment of unresectable or metastatic oesophageal squamous cell carcinoma (ESCC).

52

52

PharmExec

DECEMBER 30, 2024

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Media 52

Media 52

Advertiser: ZoomInfo

Over the last two years, there’s been a 76 percent increase in AI adoption across sales organizations. The reason for its rise? AI increases teams’ productivity by predicting and automating actions that require manual effort. In other words, the research that takes reps hours, AI can do in seconds. For sales teams, AI opens up a world of new possibilities, including automating outreach, identifying best-fit buyers, and keeping CRMs flush with fresh data.

Sales

Pharmacy Times

DECEMBER 30, 2024

The disparity highlights opportunities for pharmacists to get involved and address health disparities.

Patients 47

Patients 47

Pharmaceutical Technology

DECEMBER 30, 2024

ITM-91 is under clinical development by ITM Isotope Technologies Munich and currently in Phase II for Pancreatic Ductal Adenocarcinoma.

40

40

Pharmacy Times

DECEMBER 30, 2024

Plaintiff argues that "blacklisting certain individuals with opioid prescriptions was unlawful.

Prescription 29

Prescription Patients 29

Pharmaceutical Technology

DECEMBER 30, 2024

ITM-91 is under clinical development by ITM Isotope Technologies Munich and currently in Phase II for Metastatic Colorectal Cancer.

40

40

Advertisement

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

Sales

Pharmacy Times

DECEMBER 30, 2024

Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia.

Management 26

Management 26

Pharmaceutical Technology

DECEMBER 30, 2024

CT-7439 is under clinical development by Carrick Therapeutics and currently in Phase I for Breast Cancer.

40

40

Pharmacy Times

DECEMBER 30, 2024

Panelists discuss understanding the comparative advantages, decision-making factors, infrastructure requirements, and partnership models for administering bispecific antibodies in community vs academic settings, with particular focus on patient care logistics and referral pathways.

Patients 26

Patients 26

Pharmaceutical Technology

DECEMBER 30, 2024

Iptacopan hydrochloride is under clinical development by Novartis and currently in Phase II for Granulomatosis with Polyangiitis (Wegener's Granulomatosis).

40

40

Advertiser: ZoomInfo

Modern go-to-market teams know it takes more than one email to break through the noise. Multiple touchpoints means more ways to get your pitch right — and, potentially, more ways to be wrong. The good news? Once you know how to write compelling, one-off emails to entice prospective customers, you can easily do the same across a short sequence of emails.

Prospecting

Pharmacy Times

DECEMBER 30, 2024

Panelists discuss how key recommendations for optimizing bispecific therapy care focus on establishing robust communication protocols between academic and community centers while ensuring community centers develop comprehensive infrastructure including staff training, emergency protocols, and care coordination pathways.

Training 26

Training Patients 26

Pharmaceutical Technology

DECEMBER 30, 2024

Tevimbra is under clinical development by BeiGene and currently in Phase II for Gallbladder Cancer.

40

40

MedCity News

DECEMBER 30, 2024

December saw a slew of executive hires, promotions, exits and layoffs across the healthcare industry. For example, companies like Humana and Mayo Clinic hired new C-suite leaders, organizations including Atlantic Health System and Amwell are saying goodbye to key executives, and firms like CVS Health and Optum announced rounds of job cuts. The post Healthcare Moves: A Monthly Summary of Hires, Exits and Layoffs appeared first on MedCity News.

Healthcare 89

Healthcare Healthcare 89

Pharmaceutical Technology

DECEMBER 30, 2024

Tevimbra is under clinical development by BeiGene and currently in Phase II for Muscle Invasive Bladder Cancer (MIBC).

40

40

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patients

MedCity News

DECEMBER 30, 2024

While worries about the affordability of care are sure to persist for many Americans over the coming year, here are some other patient payment trends for providers to watch The post 2025 Trends to Watch in Patient Payments appeared first on MedCity News.

Patients 89

Patients Medical Healthcare Healthcare 89

Pharmaceutical Technology

DECEMBER 30, 2024

NVP-1805R2 is under clinical development by NVP Healthcare and currently in Phase I for Unspecified Cardiovascular Disorders.

Healthcare 40

Healthcare Healthcare 40

MedCity News

DECEMBER 30, 2024

Addressing difficult-to-treat diseases and disorders, quickly, safely, and with little to no side effects is a positive boon to our overburdened health system. The post The Same Processes that Make Smartphones a Risk for Young People Must Be Harnessed to Provide Beneficial Digital Medical Treatments For All appeared first on MedCity News.

Side effects 86

Side effects Medical Media Physicians 86

Pharmaceutical Technology

DECEMBER 30, 2024

Xaluritamig is under clinical development by Amgen and currently in Phase I for Prostate Cancer.

40

40

Advertiser: ZoomInfo

Account-based marketing (ABM) is a key strategy for driving sustainable growth. Today, many B2B companies use ABM teams or technologies to make sales. But getting a program off the ground successfully doesn’t have to be a daunting task. Watch this webinar with Rachael Foster, Director of Account-Based Experience at ZoomInfo, and Dan Dolph, Manager of Account-Based Experience at ZoomInfo.

Sales